Literature DB >> 7804734

Molecular genetics of familial venous thrombosis.

D N Cooper1, E G Tuddenham.   

Abstract

Mutations in a variety of human genes are now known to predispose to venous thrombosis. Study of these mutations has led to important advances in our understanding of the structure and function of haemostatic regulatory proteins and has facilitated accurate presymptomatic and antenatal diagnosis. However, owing to the probabilistic nature of thromboembolism, only a certain proportion of patients with a recognized gene defect in the heterozygous state will actually suffer from thrombotic episodes. Allelic heterogeneity, epistatic effects resulting from the influence of other loci and environmental insults of various kinds all play a role in determining whether a thrombotic event occurs in individuals already compromised by a gene defect. Nevertheless, characterization of the wide spectrum of gene mutations giving rise to thrombosis may allow us to relate specific gene lesions to the probability of thromboembolism as well as to the severity and frequency of thrombotic episodes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7804734     DOI: 10.1093/oxfordjournals.bmb.a072929

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  3 in total

Review 1.  A guide to venous thromboembolism risk factor assessment.

Authors:  G D Motykie; L P Zebala; J A Caprini; C E Lee; J I Arcelus; J J Reyna; E B Cohen
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

2.  Long-term expression of human coagulation factor VIII in a tolerant mouse model using the φC31 integrase system.

Authors:  Christopher L Chavez; Annahita Keravala; Jacqueline N Chu; Alfonso P Farruggio; Vanessa E Cuéllar; Jan Voorberg; Michele P Calos
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

3.  Myeloid/natural killer cell precursor acute leukemia accompanied by homozygous protein C deficiency.

Authors:  Takashi Shimamoto; Akihiro Nakajima; Tomoko Katagiri; Yoshikazu Ito; Kazuma Ohyashiki
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.